Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes

Reuters03-13 21:05

Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes

Sana reported 14-month follow-up results from an investigator-sponsored first-in-human study in type 1 diabetes that transplanted UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform, into a patient without immunosuppression. The company said the full 14-month dataset will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference. At month 14, fasting and mixed meal tolerance test-stimulated C-peptide levels were reported as comparable to the first 6 months and higher than levels at months 9 and 12. Sana said no safety issues were identified and that C-peptide increased in response to the mixed meal tolerance test, consistent with meal-stimulated insulin secretion. Sana also said it expects to file an investigational new drug application for SC451 and start a Phase 1 trial as early as this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130900PRIMZONEFULLFEED9671481) on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619119086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619119086","market":"nz","top_or_hot":-1,"title":"Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sana reported 14-month follow-up results from an investigator-sponsored first-in-human study in type 1 diabetes that transplanted UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform, into a patient without immunosuppression. The company said the full 14-month dataset will be presented at the Advanced Technologies &amp; Treatments for Diabetes (ATTD) conference. At month 14, fasting and mixed meal tolerance test-stimulated C-peptide levels were reported as comparable to the first 6 months and higher than levels at months 9 and 12. Sana said no safety issues were identified and that C-peptide increased in response to the mixed meal tolerance test, consistent with meal-stimulated insulin secretion. Sana also said it expects to file an investigational new drug application for SC451 and start a Phase 1 trial as early as this year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SANA\">Sana Biotechnology</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130900PRIMZONEFULLFEED9671481) on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-13 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sana reported 14-month follow-up results from an investigator-sponsored first-in-human study in type 1 diabetes that transplanted UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform, into a patient without immunosuppression. The company said the full 14-month dataset will be presented at the Advanced Technologies &amp; Treatments for Diabetes (ATTD) conference. At month 14, fasting and mixed meal tolerance test-stimulated C-peptide levels were reported as comparable to the first 6 months and higher than levels at months 9 and 12. Sana said no safety issues were identified and that C-peptide increased in response to the mixed meal tolerance test, consistent with meal-stimulated insulin secretion. Sana also said it expects to file an investigational new drug application for SC451 and start a Phase 1 trial as early as this year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SANA\">Sana Biotechnology</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130900PRIMZONEFULLFEED9671481) on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL37VnlV:1","article_id":"2619119086","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619119086","pubTimestamp":1773407136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sana reported 14-month follow-up results from an investigator-sponsored first-in-human study in type 1 diabetes that transplanted UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform, into a patient without immunosuppression. The company said the full 14-month dataset will be presented at the Advanced Technologies & Treatments for Diabetes  conference. At month 14, fasting and mixed meal tolerance test-stimulated C-peptide levels were reported as comparable to the first 6 months and higher than levels at months 9 and 12. Sana said no safety issues were identified and that C-peptide increased in response to the mixed meal tolerance test, consistent with meal-stimulated insulin secretion. Sana also said it expects to file an investigational new drug application for SC451 and start a Phase 1 trial as early as this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SANA":"Sana Biotechnology, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Sana报告1型糖尿病UP421免疫低下胰岛移植研究14个月阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SANA":0.9,"NDAQ":0.9},"content_text":"Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes\n    \n\n        Sana reported 14-month follow-up results from an investigator-sponsored first-in-human study in type 1 diabetes that transplanted UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune platform, into a patient without immunosuppression. The company said the full 14-month dataset will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference. At month 14, fasting and mixed meal tolerance test-stimulated C-peptide levels were reported as comparable to the first 6 months and higher than levels at months 9 and 12. Sana said no safety issues were identified and that C-peptide increased in response to the mixed meal tolerance test, consistent with meal-stimulated insulin secretion. Sana also said it expects to file an investigational new drug application for SC451 and start a Phase 1 trial as early as this year.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130900PRIMZONEFULLFEED9671481) on March 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619119086","isCrawlerRequest":true}